Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aliza Thompson

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Nature Reviews. Nephrology|March 7, 2012
Proteinuria as a surrogate end point--more data are neededAliza Thompson
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 23, 2018
African Americans, Kidney Disease, and Drug Development: A Regulatory PerspectiveCarolina Panico, Aliza Thompson
Therapeutic Innovation & Regulatory Science|April 20, 2021
Value of Data Sharing to Advance Drug Development: A Regulatory PerspectiveAliza Thompson, Ameeta Parekh
Expert Opinion on Drug Metabolism & Toxicology|August 14, 2018
Biomarkers of drug-induced acute kidney injury: a regulatory perspectiveMelanie Blank, Aliza Thompson, Elizabeth Hausner, et al.
Journal of the American Society of Nephrology : JASN|June 17, 2015
Complete and Partial Remission as Surrogate End Points in Membranous NephropathyAliza Thompson, Daniel C Cattran, Melanie Blank, et al.
Diabetes, Obesity & Metabolism|October 9, 2018
Precision medicine in diabetes and diabetic kidney disease: Regulatory considerationsPeter G M Mol, Aliza Thompson, Hiddo J L Heerspink, et al.
Clinical Pharmacology and Therapeutics|May 16, 2018
Evaluating the Use of KIM-1 in Drug Development and Research Following FDA QualificationRu Chen, Sarmistha Sanyal, Aliza Thompson, et al.
Lupus|March 3, 2022
Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspectiveTao Liu, Rosemarie Neuner, Aliza Thompson, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 15, 2022
Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug AdministrationLesley A Inker, Morgan E Grams, Hrefna Guðmundsdóttir, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 5, 2016
Patient-Reported Outcomes in Glomerular DiseaseDavid T Selewski, Aliza Thompson, Sarrit Kovacs, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Nature Reviews. Nephrology|March 7, 2012
Proteinuria as a surrogate end point--more data are neededAliza Thompson
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 23, 2018
African Americans, Kidney Disease, and Drug Development: A Regulatory PerspectiveCarolina Panico, Aliza Thompson
Therapeutic Innovation & Regulatory Science|April 20, 2021
Value of Data Sharing to Advance Drug Development: A Regulatory PerspectiveAliza Thompson, Ameeta Parekh
Expert Opinion on Drug Metabolism & Toxicology|August 14, 2018
Biomarkers of drug-induced acute kidney injury: a regulatory perspectiveMelanie Blank, Aliza Thompson, Elizabeth Hausner, et al.
Journal of the American Society of Nephrology : JASN|June 17, 2015
Complete and Partial Remission as Surrogate End Points in Membranous NephropathyAliza Thompson, Daniel C Cattran, Melanie Blank, et al.
Diabetes, Obesity & Metabolism|October 9, 2018
Precision medicine in diabetes and diabetic kidney disease: Regulatory considerationsPeter G M Mol, Aliza Thompson, Hiddo J L Heerspink, et al.
Clinical Pharmacology and Therapeutics|May 16, 2018
Evaluating the Use of KIM-1 in Drug Development and Research Following FDA QualificationRu Chen, Sarmistha Sanyal, Aliza Thompson, et al.
Lupus|March 3, 2022
Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspectiveTao Liu, Rosemarie Neuner, Aliza Thompson, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 15, 2022
Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug AdministrationLesley A Inker, Morgan E Grams, Hrefna Guðmundsdóttir, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 5, 2016
Patient-Reported Outcomes in Glomerular DiseaseDavid T Selewski, Aliza Thompson, Sarrit Kovacs, et al.
Pageof 3